BioPorto

Update in progress

BIOPOR.CO (Copenhagen)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

BioPorto A/S is an in vitro diagnostics company that develops biomarker tests to help clinicians detect kidney injury earlier in critically ill patients. Based in Hellerup, Denmark, it serves Europe, North America and Asia. Its offerings include ProNephro AKI (NGAL) for pediatric AKI, the NGAL Test for quantifying NGAL in urine and blood, antibodies for diagnostic immunoassays, ready-to-use NGAL ELISA kits, and the generic Rapid Assay Device (gRAD) for custom lateral flow assays. Founded 1917.

Company score

Sentiment: 0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.49; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.34; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive